1 September 2021 — Inventia Life Science, a Sydney-based biotechnology company, and Xylyx Bio, a New York-based leader in advanced biomaterials, today announced their strategic partnership following ...

24 August 2021 — Inventia Life Science, together with BioLamina AB, a Swedish biotechnology company leading in matrix biology and cell culture-based research, have entered into a partnership in order ...

SYDNEY--(BUSINESS WIRE)--Inventia Life Science, a world leader in advanced 3D cell cultures for research and clinical purposes, has today announced the close of a US $25M Series B funding round, led ...

Inventia Life Science, an innovator in 3D cell culture technologies, announces the launch of RASTRUM(TM) Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug ...

Inventia Rastrum—a winner of Fast Company’s 2020 World Changing Ideas Awards—uses the technology of an inkjet printer to create lifelike human cell structures so biologists can see how drugs work on ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

PERTH, Australia – Startup Inventia Life Science Pty. Ltd. has received two major investments from the Australian government to accelerate the development of a robotic device that prints a patient’s ...

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic ...

Company aims to democratize access to affordable biomedical research especially in cancer research and new drug development through its novel 3D cell culture platform SYDNEY--(BUSINESS WIRE)--Inventia ...

RASTRUM Allegro addresses key challenges faced by researchers, including the need for consistent, scalable 3D models that generate meaningful insights and limited availability of patient-derived cells ...

PERTH, Australia – Inventia Life Science Pty. Ltd. closed a A$35m (US$25 million) series B round that will see the company bring its Rastrum 3D cell culture platform to the U.S. market. The technology ...

Article ‘Count’ and ‘Share’ for Inventia Life Science Pty Ltd. based on listed parameters only. According to the parameters selected above, there are no articles from Inventia Life Science Pty Ltd.